Why would anyone be willing to sit and wait for recurrence and metastasis when treating synovial sarcoma?

时间：2026-04-27　人气：

If you cannot understand the subsequent professional description,

you can finish reading this text in two minutes

In mid-February 2020, Ms. Liu accidentally touched a mass on her right waist, about the size of a Mantou. She then visited a local hospital, where preliminary examination found that the mass was painless and had poor mobility.

"Painless and poor mobility"is a relatively dangerous description, indicating a high possibility of malignancy. In addition to imaging examinations, confirmation through pathological biopsyis also necessary.

Subsequent biopsy of the lesion confirmed synovial sarcoma. The tissue origin is synovium.

From March to April 2020, two cycles of chemotherapy were immediately administered, using the regimen of adriamycin + dacarbazine + ifosfamide. After the first chemotherapy session, the mass significantly shrunk, but there was no significant change after the second session. Subsequently, AI-based chemotherapy was administered

. In May 2020, lumbar tumor resection and internal fixation were performed at Peking University First Hospital. Post-surgery, three cycles of chemotherapy with dacarbazine + ifosfamide + liposomal paclitaxel were administered.

Traditional treatment has temporarily come to an end, and the usual approach is to only start the next stage of treatment when the tumor recurs and metastasizes.

However, no patient would be willing to sit at home waiting for recurrence and metastasis to begin a new round of various treatments! Is there a way to intervene in advance to reduce the probability of recurrence and metastasis, or even prevent them altogether? Sarcomas originating from mesenchymal tissue are relatively rare among malignant tumors. Sarcomas have a short survival period and are prone to metastasize to the lungs or other organs. Traditional treatment options have shown little effect, and patients, after undergoing various treatments, not only face significant economic burdens but also often suffer from severe physical damage caused by drugs. Ms. Liu was very worried and actively sought other methods online. After hearing about Professor Zhang Minghui of Tsinghua University and his NKT cell therapy technology, she researched many cases in detail and found that many patients who aimed for prevention had remained problem-free for over 5 years! This fact gave Ms. Liu great confidence and she contacted our team. After a detailed understanding of her condition, we developed a treatment plan for Ms. Liu with one course per month. Treatment began in August 2020 and has continued to date, with 11 courses completed (as of July 2021). There has been no evident tumor progression, and the evaluation is stable. Imaging-wise: Chest CT scans from October 2020 to April 2021 showed no significant abnormalities; lumbar MRI scans from October 2020 to April 2021 revealed edema in the bilateral erector spinae muscles without evident tumor signs, considered to be post-operative changes. A follow-up whole-body PET-CT scan in August 2021 showed no signs of recurrence or metastasis.

▲Lumbar M-spinal muscle still shows edema, with no obvious tumor signs. On April 27, 2021 (T2WI axial), no obvious tumor signs were observed. Currently, it is considered to be a postoperative change.

▲PET-CT (August 16, 2021): After treatment for lumbar synovial sarcoma, high-density implants were observed in the surgical area, with good alignment and no obvious loosening. FDG metabolic activity increased near the transverse process around the metal fixation, which is considered to be an inflammatory reactive change. Local vertebral postoperative changes were observed, with no obvious increase in FDG metabolism, indicating no clear signs of tumor recurrence.

▲Lung imaging findings: Residual thymus was visible, with no other abnormalities or metastasis observed.

Quality of life:

During the one-year treatment, Ms. Liu's physical condition significantly improved, with better appetite and sleep, increased body weight, resuming normal work, and excellent mental state. Her quality of life score was 91.5.

Ms. Liu underwent surgery in May 2020 and began NKT cell immunotherapy on August 28, 2020. Currently, her disease-free survival (DFS) has reached 17 months. For malignant tumors such as lumbar synovial sarcoma, which have a high recurrence rate and short survival period, Ms. Liu's treatment has been very effective.

Let's look forward to next year's follow-up presentation together.

Review of NKT classic cases

Click on the image

to view

上一篇：肺癌术后，仅6个月就出现脑转移，两次复发后使用该方法遏制

下一篇：不愿在家坐等第三次转移，肾癌的他这样选择

About Lehe

Corporate Culture Founder's Introduction Lehe News Story of Lehe Science Popularization Academic Literature

New Medical Services

Second Consultation Rehabilitation and Wellness Elite Care

Oncology Clinical Research

Lung Cancer Stomach Cancer Hepatobiliary and Pancreatic Cancers Intestine Cancer Breast Cancer B-cell lymphoma Cervical Cancer Other Solid Tumors

Chronic Disease Research

Hypertension Diabetes Obesity Immune Diseases Degenerative Diseases Chronic Inflammation Others

Contact Us

Address: Room 1101 (Unit 101), 11th Floor, Building 1, No. 7 Courtyard, Kexueyuan Road, Life Science Park, Changping District, Beijing
Phone：010-8265 9866
Email：lehemedneo@hotmail.com

Copyright©2022 Beijing Lehe New Medical Clinic Co., Ltd. All Rights Reserved ICP: 京ICP备2025148232号京公网安备11011402054997号 Privacy Policy